Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Tomomi Nakamura, MD"'
Autor:
Kazushige Wakuda, MD, Hiroyuki Yamaguchi, MD, PhD, Hirotsugu Kenmotsu, MD, PhD, Minoru Fukuda, MD, PhD, Kentaro Ito, MD, Yuko Tsuchiya-Kawano, MD, PhD, Kentaro Tanaka, MD, PhD, Taishi Harada, MD, PhD, Yuki Nakatani, MD, Satoru Miura, MD, Toshihide Yokoyama, MD, Tomomi Nakamura, MD, Miiru Izumi, MD, PhD, Atsushi Nakamura, MD, PhD, Satoshi Ikeda, MD, PhD, Koichi Takayama, MD, PhD, Kenichi Yoshimura, PhD, Kazuhiko Nakagawa, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Kenji Sugio, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100587- (2023)
Introduction: Osimertinib may be effective in treating central nervous system (CNS) metastasis, but its efficacy in treating radiation therapy (RT)-naive metastasis is unclear. The OCEAN study assessed the efficacy of osimertinib against RT-naive CNS
Externí odkaz:
https://doaj.org/article/2430d3ab5e8943f5b2079f35a13f2fad
Autor:
Atsushi Osoegawa, MD, PhD, Masafumi Yamaguchi, MD, PhD, Tomomi Nakamura, MD, PhD, Ryotaro Morinaga, MD, Kentaro Tanaka, MD, PhD, Kosuke Kashiwabara, MD, PhD, Takashi Miura, MD, PhD, Takayuki Suetsugu, MD, PhD, Taishi Harada, MD, PhD, Tatsuma Asoh, MD, PhD, Kenichi Taguchi, MD, PhD, Kazuki Nabeshima, MD, PhD, Junji Kishimoto, MA, Kazuko Sakai, PhD, Kazuto Nishio, MD, PhD, Kenji Sugio, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 7, Pp 100191- (2021)
Introduction: Although treatment with osimertinib confers survival benefits in patients with lung cancer with the EGFR T790M mutation, the mechanism of acquired resistance to osimertinib remains poorly understood. We conducted a prospective observati
Externí odkaz:
https://doaj.org/article/3325e96eb81945d7a9c2b5e282c36d99